Your browser doesn't support javascript.
loading
Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study.
Liu, Zhigang; Le, Kaixing; Zhou, Xin; Alexander, James L; Lin, Simeng; Bewshea, Claire; Chanchlani, Neil; Nice, Rachel; McDonald, Timothy J; Lamb, Christopher A; Sebastian, Shaji; Kok, Klaartje; Lees, Charlie W; Hart, Ailsa L; Pollok, Richard C; Boyton, Rosemary J; Altmann, Daniel M; Pollock, Katrina M; Goodhand, James R; Kennedy, Nicholas A; Ahmad, Tariq; Powell, Nick.
Afiliação
  • Liu Z; Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.
  • Le K; Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.
  • Zhou X; Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.
  • Alexander JL; Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK; Department of Gastroenterology, Imperial College Healthcare NHS Trust, London, UK.
  • Lin S; Department of Gastroenterology, Royal Devon University Healthcare NHS Foundation Trust, Exeter, UK; Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter, Exeter, UK.
  • Bewshea C; Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter, Exeter, UK.
  • Chanchlani N; Department of Gastroenterology, Royal Devon University Healthcare NHS Foundation Trust, Exeter, UK; Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter, Exeter, UK.
  • Nice R; Department of Biochemistry, Exeter Clinical Laboratory International, Royal Devon University Healthcare NHS Foundation Trust, Exeter, UK; Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter, Exeter, UK.
  • McDonald TJ; Department of Biochemistry, Exeter Clinical Laboratory International, Royal Devon University Healthcare NHS Foundation Trust, Exeter, UK.
  • Lamb CA; Department of Gastroenterology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK; Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
  • Sebastian S; Hull York Medical School, University of Hull, Hull, UK; Department of Gastroenterology, Hull University Teaching Hospitals NHS Trust, Hull, UK.
  • Kok K; Department of Gastroenterology, Bart's Health NHS Trust, London, UK.
  • Lees CW; Department of Gastroenterology, Western General Hospital, NHS Lothian, Edinburgh, UK; Centre for Inflammation Research, The Queen's Medical Research Institute, The University of Edinburgh, Edinburgh, UK.
  • Hart AL; Department of Gastroenterology, St Marks Hospital and Academic Institute, London, UK.
  • Pollok RC; Department of Gastroenterology, St George's University Hospitals NHS Foundation Trust, London, UK; Institute for Infection and Immunity, St George's University of London, London, UK.
  • Boyton RJ; Department of Infectious Disease, Imperial College London, London, UK; Lung Division, Royal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Altmann DM; Department of Immunology and Inflammation, Imperial College London, London, UK.
  • Pollock KM; Department of Infectious Disease, Imperial College London, London, UK; NIHR Imperial Clinical Research Facility and NIHR Imperial Biomedical Research Centre, London, UK.
  • Goodhand JR; Department of Gastroenterology, Royal Devon University Healthcare NHS Foundation Trust, Exeter, UK; Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter, Exeter, UK.
  • Kennedy NA; Department of Gastroenterology, Royal Devon University Healthcare NHS Foundation Trust, Exeter, UK; Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter, Exeter, UK.
  • Ahmad T; Department of Gastroenterology, Royal Devon University Healthcare NHS Foundation Trust, Exeter, UK; Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter, Exeter, UK.
  • Powell N; Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK; Department of Gastroenterology, Imperial College Healthcare NHS Trust, London, UK. Electronic address: npowell@imperial.ac.uk.
Lancet Gastroenterol Hepatol ; 8(2): 145-156, 2023 02.
Article em En | MEDLINE | ID: mdl-36481043
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Inflamatórias Intestinais / COVID-19 Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies Limite: Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Gastroenterol Hepatol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Inflamatórias Intestinais / COVID-19 Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies Limite: Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Gastroenterol Hepatol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Reino Unido